Neglected Side Effects to Curative Prostate Cancer Treatments
Overview
Urology
Affiliations
In this narrative review we summarize neglected side effects of curative intended treatment for prostate cancer. They include climacturia, arousal incontinence (AI), orgasmic disturbances such as altered orgasmic sensation, anorgasmia, and orgasm-associated pain (dysorgasmia), ejaculatory dysfunction, and morphological penile alterations in the form of shortening and deformity. Even though they have not received as much interest as erectile dysfunction (ED) or urinary incontinence, these side effects have been shown to negatively impact patient's quality of life. They are common and rates of climacturia after radical prostatectomy (RP) range from 20% and 45%, less after external beam radiation therapy (EBRT). Decreased orgasmic sensation ranges from 3.9% to 60% after RP and between 36-57% after EBRT. Dysorgasmia ranges from 9.5-15% for both RP and EBRT. Anejculation after EBRT ranges from 11-71% and rates of penile shortening are reported between 0 and 100%. There are no internationally validated questionnaires that adequately asses these side effects. This is necessary if we are to align patient and partner expectations properly and consequently manage them optimally. Neglected side effects should be discussed with patients and their partners preoperatively, as they are associated with bother and may lead to patient's avoiding sexual activity.
Prebay Z, Fu D, Hochberg A, Chung P Int J Impot Res. 2025; .
PMID: 39881011 DOI: 10.1038/s41443-025-01015-8.
The Prevalence of Climacturia in Patients after Radical Prostatectomy: A Systematic Review.
Ferrao J, Becker A, Bangemann G, Oliboni T, Marquardt Filho N, da Ros C Int Braz J Urol. 2024; 51(1).
PMID: 39556847 PMC: 11869926. DOI: 10.1590/S1677-5538.IBJU.2024.0406.
Health Professionals' Perceptions about Prostate Cancer-A Focus Group Study.
Leitao C, Estrela M, Monteiro L, Fardilha M, Herdeiro M, Roque F Cancers (Basel). 2024; 16(17).
PMID: 39272863 PMC: 11394291. DOI: 10.3390/cancers16173005.
Fattahi M, Dehghani M, Paknahad S, Rahiminia S, Zareie D, Hoseini B Front Oncol. 2024; 14:1438297.
PMID: 39193389 PMC: 11347329. DOI: 10.3389/fonc.2024.1438297.
Gamberini P, Nascimento B, Filho H, Nahas W, de Bessa Junior J, Teixeira T Int Urol Nephrol. 2024; 57(1):115-120.
PMID: 39153132 DOI: 10.1007/s11255-024-04181-8.